Tag: "remicade" at biology news

Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation

BARCELONA, Spain, 15 June 2007 Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE (infliximab) over two years experienced significant improvement in spinal mobility. In addition, REMICADE-treated patients showed sustained reductions in spinal inflammation thr...

Long-term ulcerative colitis study shows Remicade responders maintained improvement

... The ACT extension trials were conducted in both the United States and Europe, under co-principle investigators William Sandborn, M.D. of the Mayo Clinic and Walter Reinisch, M.D., of the Un...

New analyses reinforce efficacy of Remicade in treatment of severe psoriasis

WASHINGTON, DC, February 2, 2007 -- Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving REMICADE (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (...

Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis

WASHINGTON, D.C., February 2, 2007 -- Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving REMICADE (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50. After 10 weeks, patients receiving REMICADE 3 mg/kg...

Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial (Active Ulcerative Colitis Trial 1, ACT 1) presented at the American College of Gastroenterology (ACG) meeti...

REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement

Phase 3 data show treatment with REMICADE (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the EXPRESS II trial, a placebo-controlled, dose-ranging study of REMICADE 3 mg/kg and 5 mg/kg, showed that every eight week maintenance therapy resulted in greater long-term skin clearance compared with "as-n...

Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients

HORSHAM, Pa., and KENILWORTH, N.J., December 8, 2005 Landmark studies published today in The New England Journal of Medicine demonstrate the benefits of treatment with REMICADE (infliximab) in patients with ulcerative colitis (UC). ...... At week 8, in both the 54-week ACT 1 trial and the 30-week ACT 2 trial, statistically significant differences in the proportion of patients in clinical respon...

Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis

SAN DIEGO, CALIF., NOVEMBER 13, 2005 New data, including two-year treatment duration, show a significantly higher proportion of patients with active psoriatic arthritis receiving REMICADE (infliximab) achieved and sustained a high degree of clinical improvement in arthritis, as assessed using the rheumatoid arthritis (RA) definition for "major clinical response," compared with patients receiving...
(Date:11/5/2014)... Brazil -Individuals show great diversity in their ability to ... females greatly differ in their perceptual evaluation of odors, ... tests. , Sex differences in olfactory detection ... may be connected to one,s perception of smell, which ... women,s olfactory superiority has been suggested to be cognitive ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
Other Tags
studiesbiotechnologyopeningmarksprostheseshyenasfemurwheatsprogrammedvocabularyheartmatehyperactivitysubsidiesdistrictendotoxinsartemisinin